+826.1%
PLTR vs GSK
+65.2%
+760.9%
-48.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.5% | +2.4% | +3.1% | +5.7% |
| 7D | -5.1% | +4.9% | -10.0% | -4.7% |
| 30D | -19.1% | +10.8% | -29.9% | -18.3% |
| 3M | -1.6% | -1.8% | +0.2% | -1.7% |
| 6M | +22.8% | +4.1% | +18.7% | +23.5% |
| YTD | -4.8% | +7.9% | -12.7% | -4.5% |
| 1Y | -4.9% | +14.4% | -19.4% | -4.5% |
| 3Y | +826.1% | +68.1% | +758.0% | +865.2% |
| All | +826.1% | +65.2% | +760.9% | +865.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling